Category Archives: DNA

How to Recover Deleted Videos from HTC DNA
Download HTC DNA Droid Videos Recovery program for free to retrieve your lost videos: [Dr.Fone for Android (Windows)] http://www.phone-data-recovery.org/andr...

By: Selena Lee

Read the original here:
How to Recover Deleted Videos from HTC DNA - Video

Wanessa DNA Tour - em Teresina.
Wanessa DNA Tour - em Teresina-PI no Villa Rio.

By: ThiagoTify

See original here:
Wanessa DNA Tour - em Teresina. - Video

Dizaster: DNA Made Chilla Jones Look Like an Ant
http://www.vladtv.com/ - Dizaster opened up on his history with battling in this clip from his exclusive interview with VladTV. Diz explained that he began r...

By: djvlad

Read more here:
Dizaster: DNA Made Chilla Jones Look Like an Ant - Video

DNA CONECTIONS
Dinamismo, sin importar que edad, solo en DNA CONECTIONS...

By: Christian Dasilva

Read more from the original source:
DNA CONECTIONS - Video

3D cages made from strands of DNA could be used as a nanotechnology solution for drug delivery.

Cubes of DNA, with molecular tentacles, or chains, attached on each corner, spontaneously create water-repellant carriages that could be used to carry drugs.

In research carried out at McGill University in Canada, lipid-tipped DNA chains attached to DNA cubes folded back inside, creating places for hydrophobic molecules to be carried. The research is detailed in a paper published in Nature Chemistry on 1 September.

Importantly, the drugs are released by snipping off the tentacles. By designing the cages with specific delivery sites in mind, the tentacles could fall off when the cages arrive at the proper location, delivering the drugs to where they are most effective.

The potential for DNA cages in drug delivery partly lies in their ability to form a variety of cell-like stable structures. As a 2013 paper from Universite Bordeaux Segalen noted, "the ability of DNA to form predicatble and complex nano-architectures is virtually unlimited."

"We are able to create DNA cages with any geometry, size or shape, and that's unique among drug delivery vehicles," says Hanadi Sleiman, who led the research. "They are extremely programmable."

Finding novel ways of inducing these cages to carry a cargo and then release it at the appropriate point is currently a very active area of research. This study is the first time molecules that don't actively attach to DNA have been transported inside a DNA cage.

"[Putting molecules] in a DNA cage is difficult as the pore size is very large," says Sleiman.

To solve this problem, the team added altered DNA chains -- dendritic DNA or "D-DNA" -- to each of the corners of a DNA cube. The chains are known as "amphipiles", meaning that that they are attracted to both water and lipids. As the chains themselves have lipids on the ends, they are therefore attracted to each other.

"When there are eight amphiphiles, they engage in an intramolecular "handshake" inside the cube [] this encapsulates small molecules and releases them by DNA recognition," the team note in the paper.

See the article here:
'Highly programmable' DNA cubes could be used for drug delivery

Tiny "cages" of DNA can be used to deliver drugs to diseased cells, new research has shown.

The discovery opens up new avenues for highly-precise targeted treatments.

Scientists are conducting cell and animal studies to see if the DNA "smart bombs" can be used to tackle leukaemia and prostate cancer.

Lead scientist Professor Hanadi Sleiman, from McGill University in Canada, said: "This research is important for drug delivery, but also for fundamental structural biology and nanotechnology."

DNA carries all the genetic information of living organisms, but can also be used to build microscopic structures.

Prof Sleiman's team first created cubes from short strands of DNA, then modified them with fatty lipid molecules.

The lipids created a sticky "core" within the cube that could hold cargo such as a drug.

Scientists from the same laboratory have previously shown that gold nanoparticles can be loaded and released from DNA tubes.

The "cages" can trap much smaller particles than gold, making them suitable for medical applications.

A major advantage is that they can be designed to release drugs in the presence of a specific genetic code sequence.

Visit link:
DNA 'cages' hope for drug delivery

PLEASANTON, Calif.--(BUSINESS WIRE)--

IntegenX Inc., the leading developer of rapid human DNA identification technology, today announced that it has completed developmental validation for the RapidHIT System, the first fully automated, fully integrated rapid human DNA identification system. Data will be presented at the 25th World Congress of the International Society of Forensic Genetics in Melbourne, Australia, September 2-7, 2013.

Completion of SWGDAM (Scientific Working Group for DNA Analysis Methods) developmental validation is a key milestone necessary for the full commercialization of DNA technologies for the purposes of human identification in forensics, law enforcement, defense, homeland security, and intelligence community applications. In addition to developmental validation data including highly successful CODIS profile generation, IntegenX will present data on the use of the RapidHIT System to analyze samples routinely recovered from crime scenes, such as blood and saliva. These applications dramatically expand the utility of the RapidHIT System for use in crime scene investigation and rapid lead identification by law enforcement, defense, and the intelligence community. The ability to rapidly generate DNA profiles on a variety of biological samples fundamentally changes the way investigations are conducted by enabling forensics and law enforcement personnel to quickly link a suspects DNA to a crime scene, or eliminate suspicion, all while the suspect is still in custody.

The completion of a developmental validation study by the manufacturer is a critical important step toward establishing rapid DNA technology as reliable and robust. Rapid DNA technology will enable both forensic and law enforcement professionals to expand the use of DNA typing as a tool to solve crimes, said Dr. Bruce Budowle, Professor, Executive Director of the Institute of Applied Genetics at the University of North Texas Health Science Center.

Were thrilled at the full commercial launch of the RapidHIT System, and the significant validation dataset we have been able to generate. We look forward to helping communities and governments throughout the world implement such a game changing technology, commented Robert Schueren, President and Chief Executive Officer of IntegenX.

The IntegenX RapidHIT System fully automates and integrates all steps necessary to generate a DNA profile in approximately 90 minutes. With less than five minutes of hands-on time, a user can generate up to five complete DNA profiles, as well as a positive and negative control. DNA profiles generated by the RapidHIT System are compatible with standard databases that contain previously generated profiles from reference and crime scene sources. Combining ease of use and rapid turnaround time for DNA results will have a high impact toward ensuring the safety of our communities.

About IntegenX Inc.

IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing, forensics, and biodefense applications. For more information, please visit http://www.integenx.com.

IntegenX, the IntegenX logo, and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

Go here to see the original:
IntegenX to Present Significant Advances in Rapid DNA Technology at the 25th World Congress of the International ...

LEBANON -

The murder trial for David Camm continued Tuesday with continuing testimony from Indiana State PoliceDNA analyst Lynn Scamahorn.

In February 2005,Scamahorn tested the gray sweatshirt left at the crime scene and Charles Boney's DNA came up as a match. Also in 2005, another area of the sweatshirt tested and matched Boney's girlfriend's DNA.

The DNA analyst testified outside the presence of the jury that during the first trial in 2001, prosecutor Stan Faith threatened her because she wasn't willing to testify the way he wanted her to. He wanted her to say that she found Camm's DNA on the sweatshirt and she couldn't do that.

According to Scamahorn, Faith threatened her job and threatened to charge her with obstruction. The defense petitioned the court to allow the jury to hear about Faith's misconduct but the court upheld a previous ruling. The jury will not hear about Faith's misconduct in this trial.

The defense also petitioned the court to exclude testimony from Danny Camm, David's brother, who sold and was the beneficiary on Kim Camm's life insurance policy. The court allowed testimony about insurance and beneficiaries but no testimony about possible wrongdoing by Danny Camm.

The prosecutor maintains that money was motive for the murders of David Camm's wife and children.

The jury then heard from Shelly Romero, a former ISPK-9 trooper and friend of David Camm. She responded to the crime scene onthe night of the murders and Camm's first words to Romerowere, "Someone killed my[expletive] family."

Romerosaid Camm was adamant that the investigationbe done right. He asked Romero if she thought his kids were in heaven.

Camm became emotional in court when Romero recounted a conversation she had with him about the funeral preparations. Romero felt the investigation was going too quickly and like there was a "pack mentality" within the post against Camm.

Read this article:
DNA analyst testifies at David Camm trial

Sep. 1, 2013 Nanoscale "cages" made from strands of DNA can encapsulate small-molecule drugs and release them in response to a specific stimulus, McGill University researchers report in a new study.

The research, published online Sept. 1 in Nature Chemistry, marks a step toward the use of biological nanostructures to deliver drugs to diseased cells in patients. The findings could also open up new possibilities for designing DNA-based nanomaterials.

"This research is important for drug delivery, but also for fundamental structural biology and nanotechnology," says McGill Chemistry professor Hanadi Sleiman, who led the research team.

DNA carries the genetic information of all living organisms from one generation to the next. But strands of the material can also be used to build nanometre-scale structures. (A nanometre is one billionth of a metre -- roughly one-100,000th the diameter of a human hair.)

In their experiments, the McGill researchers first created DNA cubes using short DNA strands, and modified them with lipid-like molecules. The lipids can act like sticky patches that come together and engage in a "handshake" inside the DNA cube, creating a core that can hold cargo such as drug molecules.

The McGill researchers also found that when the sticky patches were placed on one of the outside faces of the DNA cubes, two cubes could attach together. This new mode of assembly has similarities to the way that proteins fold into their functional structures, Sleiman notes. "It opens up a range of new possibilities for designing DNA-based nanomaterials."

Sleiman's lab has previously demonstrated that gold nanoparticles can be loaded and released from DNA nanotubes, providing a preliminary proof of concept that drug delivery might be possible. But the new study marks the first time that small molecules -- which are considerably smaller than the gold nanoparticles -- have been manipulated in such a way using a DNA nanostructure, the researchers report.

DNA nanostructures have several potential advantages over the synthetic materials often used to deliver drugs within the body, says Thomas Edwardson, a McGill doctoral student and co-author of the new paper. "DNA structures can be built with great precision, they are biodegradable and their size, shape and properties can be easily tuned."

The DNA cages can be made to release drugs in the presence of a specific nucleic acid sequence. "Many diseased cells, such as cancer cells, overexpress certain genes," Edwardson adds. "In a future application, one can imagine a DNA cube that carries drug cargo to the diseased cell environment, which will trigger the release of the drug." The Sleiman group is now conducting cell and animal studies to assess the viability of this method on chronic lymphocytic leukemia (CLL) and prostate cancer, in collaboration with researchers at the Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital.

Funding for the Sleiman team's research was provided by the Natural Sciences and Engineering Research Council of Canada (NSERC), a CIHR Drug Development Training Program scholarship to Mr. Edwardson, the Canada Foundation for Innovation (CFI), the Centre for Self- Assembled Chemical Structures (CSACS) and the Canadian Institute for Advanced Research (CIFAR).

Read this article:
DNA 'cages' may aid drug delivery

By early next year, parents of newborns at two Boston hospitals will have the chance to participate in the first randomized study of the medical and ethical repercussions of sequencing the DNA of babies. The research is part of a major federal effort to finally settle a debate that has raged for years about the possible benefits and harms of finding out such information.

The five-year study, a joint effort of Boston Childrens Hospital and Brigham and Womens Hospital, was one of four proposals selected for funding, federal health officials announced Wednesday in a press conference. The National Institutes of Health will spend $25 million over five years to support the program, $6 million of which will support the Boston-based study.

The federal officials listed a litany of questions they hoped the studies, each testing a slightly different application of DNA sequencing to newborn care, would address. They included figuring out which babies might benefit most from the testing, and which genetic conditions should be search for in healthy newborns.

New parents in the Boston area who choose to participate in the research will be randomly assigned to either a group that has their infants DNA sequenced and learns the results, or a group whose babies do not undergo sequencing. The study will test whether that information helps guide the care of babies, and will monitor how pediatricians and parents react to knowing it.

Sequencing the DNA of newborns has been controversial, since the technology can reveal a vast amount of information about a baby, including risk for diseases that lie far in the future. Parents are making decisions to receive information that children might, when they are older, decide they do not want to know. Medical ethicists talk of keeping an open future for children, and knowing genetic information might influence parents relationships with their children. While the information may inform medical care, it might also create undue worry.

One of the goals, the purpose of the whole project, is for us to try and figure out in the real world whats appropriate and whats not, said Alan Beggs, director of the Manton Center for Orphan Disease Research at Childrens, who co-leads the study with Dr. Robert Green, a medical geneticist at the Brigham.

Having their genome is a resource that can be consulted at any age. If an illness occurs, or a new drug is going to be started, or if surgery is going to be considered, Beggs said, their DNA may provide clues about best treatments or important warning signs about risk factors.

Researchers plan to recruit 480 newborn babies and families: half will be healthy babies from the nursery at Brigham and Women's, and half will be from the neonatal intensive care unit at Childrens, where the DNA analysis may be helpful in determining whether there is a genetic cause of the babies health problems.

Among both pools of participants, only half of the babies will have their DNA sequenced; the other half will be followed as a comparison group.

The researchers have yet to decide what genetic risk factors they will look for in both the healthy and sick babies DNA, but Beggs said they would use guidelines released by the American College of Medical Genetics and Genomics earlier this year as a starting point.

Read the rest here:
Boston-area team to study DNA sequencing in newborn infants